First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months ...

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first ...

A new peptide-based vaccine elicited antigen-specific T cell responses in high-risk patients, demonstrating proof of concept ...

Huntsman Cancer Institute at the University of Utah is a national leader in cancer discovery and innovation. Phase 1 clinical trials are the foundation of progress in oncology, transforming scientific ...

Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has been dosed in its Phase 1 clinical trial ...

CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...

ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitor NLRP3 inhibitors are a major new class of compounds linked to a broad spectrum of inflammatory conditions ...

Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell's "powerhouse." ...

A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2004 monotherapy in patients with advanced tumors. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting ...

Zack Kubow - Real Chemistry, Inc. Good morning, everyone. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Conference Call. [Operator Instructions] It is now my pleasure to turn ...